Year: 2017
Type: review
Abstract: Mesenchymal stem cells (MSCs), an ideal cell source for regenerative therapy with no ethical issues, play an important role in diabetic foot ulcer (DFU). Growing evidence has demonstrated that MSCs transplantation can accelerate wound closure, ameliorate clinical parameters, and avoid amputation. In this review, we clarify the mechanism of preclinical studies, as well as safety and efficacy of clinical trials in the treatment of DFU. Bone marrow-derived mesenchymal stem cells (BM-MSCs), compared with MSCs derived from other tissues, may be a suitable cell type that can provide easy, effective, and cost-efficient transplantation to treat DFU and protect patients from amputation.
Source: Journal of Diabetes Research
DOI: 10.1155/2017/9328347
Authors: Yue Cao, Xiaokun Gang, Chenglin Sun, Guixia Wang
Institution: First Hospital of Jilin University
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,760
Awards: G3451572169, G7175732104, G8888420686
OpenAlex ID: W2594200592
